API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Fiocruz research observed that the drug Atazanavir was able to inhibit viral replication and to reduce the production of proteins that are related to the inflammatory process in the lungs in COVID-19.
Lead Product(s): Atazanavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020